IceCure Medical (ICCM) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free ICCM Stock Alerts $1.02 -0.18 (-15.00%) (As of 05:17 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 7:57 AM | finance.yahoo.comHere's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This YearMay 9, 2024 | americanbankingnews.comIceCure Medical (NASDAQ:ICCM) Shares Down 3.3% May 7, 2024 | prnewswire.comIndependent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published GloballyApril 19, 2024 | finance.yahoo.comHofseth Biocare ASA: HBC ANNUAL REPORT 2023April 16, 2024 | marketbeat.comIceCure Medical (NASDAQ:ICCM) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of IceCure Medical in a research report on Tuesday.April 15, 2024 | finance.yahoo.comIceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast CancerApril 6, 2024 | markets.businessinsider.comIcecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory MilestonesApril 5, 2024 | seekingalpha.comIceCure Medical Ltd. (ICCM) Q4 2023 Earnings Call TranscriptApril 4, 2024 | uk.investing.comIceCure seeks FDA clearance for new cryoablation systemApril 4, 2024 | marketbeat.comIceCure Medical (NASDAQ:ICCM) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSIceCure Medical (NASDAQ:ICCM - Get Free Report) released its earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $1.26 million during the quarter. IceCure Medical had a negative return on equity of 77.41% and a negative net margin of 535.84%. During the same period in the prior year, the business earned ($0.11) earnings per share.April 4, 2024 | marketbeat.comIceCure Medical (NASDAQ:ICCM) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $3.00 target price on shares of IceCure Medical in a report on Thursday.April 3, 2024 | prnewswire.comIceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing ClearanceApril 2, 2024 | prnewswire.comIceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with CryoprobesMarch 28, 2024 | marketbeat.comIceCure Medical (ICCM) Scheduled to Post Quarterly Earnings on WednesdayIceCure Medical (NASDAQ:ICCM) will be releasing earnings before the market opens on Wednesday, April 3, Zacks reports.March 27, 2024 | prnewswire.comIceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024March 20, 2024 | marketbeat.comIceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.90 at Alliance Global PartnersAlliance Global Partners increased their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a "buy" rating in a research report on Wednesday.March 20, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of IceCure Medical in a research note on Wednesday.March 19, 2024 | markets.businessinsider.comIceCure Medical: ICE3 Cryoablation Breast Cancer Study Shows Positive ResultsMarch 19, 2024 | finance.yahoo.comIceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to LumpectomyMarch 13, 2024 | marketbeat.comIceCure Medical Ltd (NASDAQ:ICCM) Short Interest UpdateIceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling 568,600 shares, a growth of 103.7% from the February 14th total of 279,100 shares. Currently, 2.8% of the shares of the company are short sold. Based on an average daily volume of 555,200 shares, the short-interest ratio is currently 1.0 days.March 12, 2024 | prnewswire.comIceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient OutcomesMarch 7, 2024 | prnewswire.comIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceMarch 7, 2024 | prnewswire.comIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services ConferenceMarch 5, 2024 | markets.businessinsider.comIceCure Medical: Strong Buy on Promising Clinical Results and Positive FDA DevelopmentsMarch 5, 2024 | marketbeat.comIceCure Medical (NASDAQ:ICCM) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of IceCure Medical in a research note on Tuesday.March 4, 2024 | prnewswire.comIceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024March 3, 2024 | marketbeat.comIceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Increase in Short InterestIceCure Medical Ltd (NASDAQ:ICCM - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 279,100 shares, a growth of 49.2% from the January 31st total of 187,100 shares. Approximately 1.4% of the company's shares are sold short. Based on an average trading volume of 2,200,000 shares, the days-to-cover ratio is presently 0.1 days.February 27, 2024 | prnewswire.comFourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions WorkshopFebruary 26, 2024 | prnewswire.comStudy Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast CancerFebruary 24, 2024 | msn.comIceCure Medical (ICCM) Price Target Increased by 5.85% to 3.14February 15, 2024 | finance.yahoo.comIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in JapanFebruary 15, 2024 | prnewswire.comIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in JapanFebruary 2, 2024 | marketbeat.comIceCure Medical Ltd (NASDAQ:ICCM) Expected to Earn FY2023 Earnings of ($0.28) Per ShareIceCure Medical Ltd (NASDAQ:ICCM - Free Report) - Investment analysts at Brookline Capital Management lifted their FY2023 earnings per share (EPS) estimates for shares of IceCure Medical in a report issued on Tuesday, January 30th. Brookline Capital Management analyst K. Dolliver now expects thatFebruary 1, 2024 | marketbeat.comBrookline Capital Management Analysts Cut Earnings Estimates for IceCure Medical Ltd (NASDAQ:ICCM)IceCure Medical Ltd (NASDAQ:ICCM - Free Report) - Stock analysts at Brookline Capital Management dropped their FY2027 earnings per share (EPS) estimates for shares of IceCure Medical in a research note issued on Tuesday, January 30th. Brookline Capital Management analyst K. Dolliver now expects tJanuary 30, 2024 | msn.comFDA agrees to review IceCure request for De Novo classificationJanuary 30, 2024 | finance.yahoo.comU.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast CancerJanuary 29, 2024 | finance.yahoo.comIceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master ClassJanuary 16, 2024 | finance.yahoo.comIceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of CryoablationJanuary 13, 2024 | finanznachrichten.deIceCure Medical Ltd.: IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price RuleJanuary 10, 2024 | finance.yahoo.comIceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 ResultsJanuary 3, 2024 | markets.businessinsider.comIceCure Medical Publishes Mouse Study On ProSense That Boosts Immune Response Against CancerJanuary 3, 2024 | finance.yahoo.comNew Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell ResponseDecember 13, 2023 | finance.yahoo.comStudy Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"November 29, 2023 | finance.yahoo.comIceCure's ProSense® Deepens Regulatory Approval in IndiaNovember 28, 2023 | msn.comIceCure shares rally 53% on ProSense kidney cancer studyNovember 28, 2023 | investorplace.com5 Investors Betting Big on IceCure Medical (ICCM) StockNovember 28, 2023 | msn.comWhat's Going On With IceCure Medical Ltd Stock?November 28, 2023 | finance.yahoo.comIceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control RateNovember 18, 2023 | markets.businessinsider.comOptimistic Outlook for IceCure Medical’s Stock Despite Revenue Setbacks: Vendetti’s Buy Rating AnalysisNovember 15, 2023 | msn.comIceCure stock climbs 10% amid FDA appeal, earnings report Get IceCure Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. ICCM Media Mentions By Week ICCM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ICCM News Sentiment▼0.910.55▲Average Medical News Sentiment ICCM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ICCM Articles This Week▼31▲ICCM Articles Average Week Get IceCure Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMIX News HSAQ News LUCD News CTSO News NSPR News PDEX News APYX News SRTS News MGRM News DRIO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ICCM) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IceCure Medical Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
